Alpha Tau Advances Pancreatic Cancer Trials with First European Patient & FDA Expansion

summarizeSummary

Alpha Tau announced the treatment of the first patient in its European ACAPELLA pancreatic cancer trial and received FDA approval to expand its U.S. IMPACT trial to include more patients and an additional chemotherapy regimen.

check_boxKey Events

• First Patient Treated in European ACAPELLA Trial

  Alpha Tau successfully treated the first pancreatic cancer patient in Europe with Alpha DaRT® in the ACAPELLA multicenter clinical trial, targeting inoperable locally advanced pancreatic ductal adenocarcinoma (LAPC) patients.

• FDA Approves IMPACT Trial Expansion

  The FDA approved an Investigational Device Exemption (IDE) supplement to expand the U.S. IMPACT trial, allowing for the inclusion of 10 additional patients receiving gemcitabine with Abraxane® and increasing the total trial size from 30 to 40 patients.

auto_awesomeAnalysis

Alpha Tau Medical announced significant progress in its clinical development for pancreatic cancer, a disease with high unmet medical need. The successful treatment of the first patient in the European ACAPELLA trial marks a crucial step in expanding the geographic reach and patient population for their Alpha DaRT® therapy. Concurrently, the FDA's approval to expand the U.S. IMPACT trial to include an additional standard-of-care chemotherapy regimen and increase patient enrollment demonstrates regulatory progress and broadens the potential applicability of Alpha DaRT. These developments reinforce the company's clinical strategy and could positively impact investor confidence, especially as the stock is trading near its 52-week high.